Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Common Equity (2019 - 2025)

Lyell Immunopharma's Common Equity history spans 7 years, with the latest figure at $329.1 million for Q3 2025.

  • For Q3 2025, Common Equity fell 37.98% year-over-year to $329.1 million; the TTM value through Sep 2025 reached $329.1 million, down 37.98%, while the annual FY2024 figure was $382.8 million, 41.55% down from the prior year.
  • Common Equity for Q3 2025 was $329.1 million at Lyell Immunopharma, up from $298.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.0 billion in Q2 2021 and bottomed at -$334.0 million in Q1 2021.
  • The 5-year median for Common Equity is $697.6 million (2023), against an average of $627.8 million.
  • The largest annual shift saw Common Equity surged 525.62% in 2021 before it tumbled 47.23% in 2025.
  • A 5-year view of Common Equity shows it stood at $929.8 million in 2021, then fell by 10.38% to $833.3 million in 2022, then fell by 21.4% to $655.0 million in 2023, then plummeted by 41.55% to $382.8 million in 2024, then fell by 14.03% to $329.1 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Common Equity are $329.1 million (Q3 2025), $298.9 million (Q2 2025), and $336.5 million (Q1 2025).